|
?:abstract
|
-
Objective: To master the situation of antiviral treatment for Corona Virus Disease 2019(COVID-19) and explore the key points of pharmaceutical care, thereby provide a reference for promoting clin rational administration of drug and pharmaceutical care for COVID-19 patients Methods:Retrospective anal method was adopted to analyze the antiviral treatment, clin efficacy and safety for COVID-19 outpatients from Jan 26, 2020 to Mar 12, 2020 in Guangzhou Eighth People\'s Hospital, a designated hospital for COVID-19, and the key points of pharmaceutical care was investigated Results: A total of 241 patients received antiviral treatment, accounting for 80 60% of COVID-19 patients discharged in the same period, the rate of cure was 94 19% The initial treatment was single drug therapy of lopinavir/ritonavir, arbidol and chloroquine phosphate, 29 88% of the patients needed to adjust the treatment plan During the study period, the proportion of treatment with lopinavir/ritonavir decreased gradually and the proportion of arbidol and chloroquine phosphate increased successively 71 Patients (29 46%) had antiviral drug-related ADRs Conclusion: The clin treatment of COVID-19 was mainly antiviral monotherapy The commonly used drugs were lopinavir/ritonavir, arbidol and chloroquine phosphate, the latter two drugs were gradually optimized in clin treatment It was necessary to monitor the gastrointestinal reaction, ECG, liver and kidney function during the treatment, and avoid adverse DDIs Meanwhile, the individual treatment and pharmaceutical care for severe and critical patients should be strengthened
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}